News

Themis presents Phase II interim results for Chikungunya vaccine candidate at ASTMH 2017

Details

Themis announced positive interim results from an ongoing phase 2 clinical study designed to demonstrate safety and immunogenicity of MV-CHIK, its live attenuated prophylactic vaccine candidate for chikungunya fever. The data will be presented for the first time at the Annual Meeting of the American Society of Tropical Medicine and Hygiene (ASTMH) in Baltimore, MA, USA. 

Ambu acquires Wellington Partners portfolio company invendo medical

Details

Today, Ambu A/S – a leader in the development, manufacture and marketing of single-use devices for hospitals – has agreed to acquire invendo medical GmbH for a purchase price of up to EUR 225m. invendo medical is a leading developer of sterile, single-use HD endoscopy products in the field of gastroenterology and gastrointestinal surgery. 

Immatics receives $58 million in financing to develop T-cell receptor based immunotherapies

Details

Immatics today announced the completion of its Series E financing, raising $58 million. 

  1. Immatics initiates first Phase I clinical trial of ACTengine® approach in patients with advanced solid cancers
  2. Wellington featured in BioCentury
  3. MSD to acquire Rigontec
  4. Themis: Chikungunya vaccine development towards Phase III trials receives £ 3 Mio. boost by Innovate UK
© Wellington Partners, 2018.